{"id":171180,"date":"2019-04-01T06:30:37","date_gmt":"2019-03-31T22:30:37","guid":{"rendered":"http:\/\/www.cailiaoniu.com\/?p=171180"},"modified":"2019-03-31T21:58:05","modified_gmt":"2019-03-31T13:58:05","slug":"%e3%80%90%e5%b7%b2%e6%a0%a1%e7%a8%bf%e3%80%91%e5%9b%bd%e5%ae%b6%e7%ba%b3%e7%b1%b3%e7%a7%91%e5%ad%a6%e4%b8%ad%e5%bf%83adv-mater-%e7%bb%bc%e8%bf%b0%ef%bc%9a%e5%ae%9a%e5%88%b6%e7%ba%b3%e7%b1%b3","status":"publish","type":"post","link":"http:\/\/www.cailiaoniu.com\/?p=171180","title":{"rendered":"\u56fd\u5bb6\u7eb3\u7c73\u79d1\u5b66\u4e2d\u5fc3Adv. Mater. \u7efc\u8ff0\uff1a\u5b9a\u5236\u7eb3\u7c73\u6750\u6599\u9776\u5411\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de"},"content":{"rendered":"

\u3010\u5f15\u8a00\u3011<\/strong><\/p>\n

\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u80fd\u591f\u8c03\u8282\u81ea\u8eab\u514d\u75ab\u7cfb\u7edf\u5e76\u6062\u590d\u673a\u4f53\u6b63\u5e38\u7684\u6297\u80bf\u7624\u514d\u75ab\u53cd\u5e94\u3002\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u57fa\u7840\u7814\u7a76\u7684\u5173\u952e\u8fdb\u6b65\u5df2\u7ecf\u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u53d6\u5f97\u663e\u8457\u7684\u6cbb\u7597\u6548\u679c\uff0c\u6781\u5927\u6539\u5584\u4e86\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u751f\u6d3b\u8d28\u91cf\u3002\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u4e3b\u8981\u5305\u62ec\u8fc7\u7ee7\u6027\u7ec6\u80de\u514d\u75ab\u6cbb\u7597\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u764c\u75c7\u75ab\u82d7\u4ee5\u53ca\u514d\u75ab\u7cfb\u7edf\u8c03\u8282\u5242\u3002\u5176\u4e2d\u4e34\u5e8a\u53d1\u5c55\u6700\u5feb\u7684\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u4e3b\u8981\u5305\u62ec\u6297\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u86cb\u767d1\uff08programmed death 1, PD-1\uff09\u6297\u4f53\u4ee5\u53ca\u7ec6\u80de\u6bd2\u6027T\u6dcb\u5df4\u7ec6\u80de\u6297\u539f4\uff08cytotoxic T-lymphocyte antigen 4, CTLA-4\uff09\u6291\u5236\u5242\u3002\u3002\u5b9e\u9645\u4e0a\uff0c\u901a\u8fc7\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u5145\u5206\u6fc0\u6d3b\u514d\u75ab\u7cfb\u7edf\u662f\u4e00\u4e2a\u7f13\u6162\u7684\u8fc7\u7a0b\uff0c\u5c24\u5176\u5bf9\u4e8e\u665a\u671f\u764c\u75c7\u60a3\u8005\u3002\u540c\u65f6\uff0c\u60a3\u8005\u7684\u7279\u5f02\u6027\u514d\u75ab\u72b6\u6001\u3001\u9057\u4f20\u3001\u80bf\u7624\u7c7b\u578b\u548c\u73af\u5883\u66b4\u9732\u7b49\u8bf8\u591a\u56e0\u7d20\u90fd\u4f1a\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u7684\u6548\u679c\u3002\u7eb3\u7c73\u6750\u6599\u7531\u4e8e\u5176\u591a\u6837\u7684\u7269\u7406\u548c\u5316\u5b66\u6027\u8d28\u53ef\u4ee5\u7528\u4f5c\u514d\u75ab\u8c03\u8282\u5242\uff0c\u7136\u800c\u5bf9\u514d\u75ab\u7cfb\u7edf\u7684\u6bd2\u6027\u4ee5\u53ca\u80bf\u7624\u7684\u4f4e\u54cd\u5e94\u7387\u4ecd\u7136\u662f\u80bf\u7624\u514d\u75ab\u7eb3\u7c73\u836f\u7269\u5728\u4e34\u5e8a\u524d\u548c\u4e34\u5e8a\u5f00\u53d1\u4e2d\u9762\u4e34\u7684\u4e24\u4e2a\u91cd\u8981\u74f6\u9888\u3002<\/p>\n

\u3010\u6210\u679c\u7b80\u4ecb\u3011<\/strong><\/p>\n

\u8fd1\u65e5\uff0c\u56fd\u5bb6\u7eb3\u7c73\u79d1\u5b66\u4e2d\u5fc3\u9648\u6625\u82f1\u7814\u7a76\u5458\uff08\u901a\u8baf\u4f5c\u8005\uff09<\/strong>\u5728Advanced Materials<\/strong>\u4e0a\u53d1\u8868\u4e86\u9898\u4e3a\u201c<\/strong>Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages<\/strong>\u201d<\/strong>\u7684\u7efc\u8ff0\u3002\u5728\u8be5\u7efc\u8ff0\u4e2d\uff0c\u9996\u5148\u603b\u7ed3\u4e86\u9776\u5411\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de(TAM)\u7684\u6548\u5e94\u673a\u5236\u4ee5\u53ca\u65b0\u578b\u514d\u75ab\u7eb3\u7c73\u836f\u7269\u5f00\u53d1\u7684\u673a\u5236\u3002\u7136\u540e\u8ba8\u8bba\u4e86\u4f7f\u7528\u4e0d\u540c\u7c7b\u578b\u7684\u7eb3\u7c73\u9897\u7c92\u9776\u5411TAM\u8fdb\u884c\u514d\u75ab\u6cbb\u7597\u4ee5\u53ca\u5bf9TAMs\u8fdb\u884c\u6210\u50cf\u4ee5\u9884\u6d4b\u60a3\u8005\u4e34\u5e8a\u6cbb\u7597\u6548\u679c\u7b49\u8fdb\u5c55\u3002\u6700\u540e\uff0c\u5f3a\u8c03\u4e86\u9776\u5411TAM\u7eb3\u7c73\u6750\u6599\u7684\u91cd\u8981\u6027\u4ee5\u53ca\u76ee\u524d\u5b58\u5728\u7684\u6311\u6218\u548c\u673a\u9047\uff0c\u6307\u51fa\u603b\u4f53\u76ee\u6807\u662f\u5229\u7528\u7eb3\u7c73\u6750\u6599\u53d1\u5c55\u5b89\u5168\u9ad8\u6548\u7684\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u3002\u7559\u5b66\u751fMuhammad Ovais\u548c\u90ed\u68a6\u96e8\u540c\u5b66\u4e3a\u5171\u540c\u7b2c\u4e00\u4f5c\u8005\u3002<\/p>\n

\u3010\u56fe\u6587\u5bfc\u8bfb\u3011<\/strong><\/p>\n

\u56fe1 \u7528\u4e8e\u9776\u5411TAM\u4fe1\u53f7\u4f20\u5bfc\u9014\u5f84\u7684\u7eb3\u7c73-\u751f\u7269\u754c\u9762<\/strong><\/p>\n

\"\"<\/p>\n

\u56fe2 \u76ee\u524d\u6b63\u5728\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\u7814\u7a76\u7684\u6297TAM\u836f\u7269\u7684\u7b5b\u9009<\/strong><\/p>\n

\"\"<\/p>\n

\u56fe3 \u9776\u5411TAM\u751f\u7269\u6750\u6599\u7684\u8bbe\u8ba1<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u4eceB. striata\u5236\u5907\u963f\u4ed1\u81a6\u9178\u591a\u7cd6\u7684\u793a\u610f\u56fe\uff1b<\/p>\n

(B) PLL-PLC\u591a\u80bd\u548csPEG\/GLC\u7eb3\u7c73\u9897\u7c92\u5236\u5907\u793a\u610f\u56fe\uff1b<\/p>\n

(C) \u7cd6\u805a\u5408\u7269\u53ca\u5176\u975e\u7cd6\u7c7b\u4f3c\u7269F-POEG-b-PS\u7684\u8bbe\u8ba1\u548c\u81ea\u7ec4\u88c5\uff1b<\/p>\n

(D) \u73af\u7cca\u7cbe\u7eb3\u7c73\u9897\u7c92\u53ca\u5176\u836f\u7269\u8d1f\u8f7d\u7684\u793a\u610f\u56fe\uff1b<\/p>\n

(E) \u88ab\u52a8\u9776\u5411\u80bf\u7624\u7684IL-12-P1\u7eb3\u7c73\u9897\u7c92\u7684\u793a\u610f\u56fe\uff1b<\/p>\n

(F) CaBP\u7eb3\u7c73\u9897\u7c92\u7684\u5236\u5907\u793a\u610f\u56fe\uff1b<\/p>\n

(G) BSA-AuNR\u7684\u5236\u5907\u8fc7\u7a0b\uff1b<\/p>\n

(H) \u91d1\u7eb3\u7c73\u9897\u7c92\u4e0eTAMs\u9776\u5411\u591a\u80bd\u548c\u786b\u9187\u5316\u6297VEGF siRNA\u7684\u7f00\u5408\u793a\u610f\u56fe\uff1b<\/p>\n

(I) CpG-GO\u7684\u5408\u6210\u53ca\u5176\u514d\u75ab\u523a\u6fc0\u4f5c\u7528\u793a\u610f\u56fe\u3002<\/p>\n

\u56fe4 \u5229\u7528\u8102\u8d28\u4f53\u8d1f\u8f7d\u7684CCR2 siRNA\u53ef\u6291\u5236\u80bf\u7624\u751f\u957f\uff0c\u51cf\u5c11TAM\u6570\u91cf<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u901a\u8fc7X\u5c04\u7ebfCT\u6d4b\u91cf\u80bf\u7624\u5927\u5c0f\uff1b<\/p>\n

(B) \u7528\u5bf9\u7167siRNA\u6216siCCR2\u5904\u7406\u540e\u80bf\u7624\u7684FACS\u5206\u6790\uff1b<\/p>\n

(C) \u80bf\u7624\u5185\u5355\u6838\u7ec6\u80de\u7684\u514d\u75ab\u7ec4\u5316\u8bc4\u4f30\uff1b<\/p>\n

(D) \u80bf\u7624\u5185\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u7684\u514d\u75ab\u7ec4\u5316\u8bc4\u4f30\uff1b<\/p>\n

(E) \u80bf\u7624\u5185\u8840\u7ba1\u5bc6\u5ea6\u7684\u514d\u75ab\u7ec4\u5316\u8bc4\u4f30\u3002<\/p>\n

\u56fe5 TAM\u9776\u5411\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u57fa\u4e8e\u7eb3\u7c73\u9897\u7c92\u7684\u5149\u54cd\u5e94ROS\u751f\u6210\u6027\u8d28\uff0c\u9006\u8f6cTAM\u8868\u578b\u8fdb\u884c\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u7684\u793a\u610f\u56fe\uff1b<\/p>\n

(B) 0\u30015\u548c12\u5929\u65f6\u4e0d\u540c\u7ec4\u522bBALA\/c\u5c0f\u9f20\u80bf\u7624\u90e8\u4f4d\u7684\u751f\u7269\u53d1\u5149\u6210\u50cf\uff1b<\/p>\n

(C) \u4e0d\u540c\u7ec4\u522bBALA\/c\u5c0f\u9f20\u7684\u80bf\u7624\u751f\u957f\u66f2\u7ebf\uff1b<\/p>\n

(D) \u4e0d\u540c\u7ec4\u522bBALA\/c\u5c0f\u9f20\u7684\u751f\u5b58\u66f2\u7ebf\u3002<\/p>\n

\u56fe6 \u7eb3\u7c73\u9897\u7c92\u7528\u4e8e\u9006\u8f6cTAM\u8868\u578b\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597<\/strong><\/p>\n

\"\"<\/p>\n

(A) MAN-PHP-PLGA\u548cMAN-PHP-PLGA-N\u7eb3\u7c73\u9897\u7c92\u5236\u5907\u793a\u610f\u56fe\uff1b<\/p>\n

(B) MAN-PHP-PLGA\u548cMAN-PHP-PLGA-N\u7eb3\u7c73\u9897\u7c92\u7684TEM\u56fe\u50cf\u548c\u5c3a\u5bf8\u5206\u5e03\u56fe\uff1b<\/p>\n

(C) 4T1\u539f\u4f4d\u80bf\u7624\u5c0f\u9f20\u7684\u751f\u7269\u53d1\u5149\u6210\u50cf\u3002<\/p>\n

\u56fe7 \u4e0d\u540c\u5206\u578b\u5de8\u566c\u7ec6\u80de\u7684\u5f62\u6001\u5b66\u8868\u5f81\u53ca\u80bf\u7624\u6cbb\u7597\u60c5\u51b5<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u80bf\u7624\u514d\u75ab\u5fae\u73af\u5883\u793a\u610f\u56fe\uff1b<\/p>\n

(B) \u4e0d\u540c\u5206\u578b\u5de8\u566c\u7ec6\u80de\u7684\u5f62\u6001\u5b66\u8868\u5f81\uff1b<\/p>\n

(C) \u5229\u7528\u5f62\u6001\u5b66\u6d4b\u5b9a\u4e0d\u540c\u5c0f\u5206\u5b50\u836f\u7269\u5bf9\u5c0f\u9f20\u5de8\u566c\u7ec6\u80de\u7684\u6781\u5316\u4f5c\u7528\uff1b<\/p>\n

(D) CDNP\u7eb3\u7c73\u9897\u7c92\u7684SEM\u56fe\u50cf\uff1b<\/p>\n

(E) \u7eb3\u7c73\u9897\u7c92\u8f7d\u836f\u91cf\u8ba1\u7b97\uff1b<\/p>\n

(F) \u80bf\u7624\u5185TAM\u6fc0\u5149\u5171\u805a\u7126\u663e\u5fae\u955c\u56fe\u50cf\uff1b<\/p>\n

(G) \u6cbb\u7597\u540e\u7b2c8\u5929\u7684\u80bf\u7624\u9762\u79ef\uff1b<\/p>\n

(H) \u4e0d\u540c\u7ec4\u522b\u5c0f\u9f20\u751f\u5b58\u66f2\u7ebf\u3002<\/p>\n

\u56fe8 \u7eb3\u7c73\u9897\u7c92CDNPs\u9776\u5411TAM<\/strong><\/p>\n

\"\"<\/p>\n

(A, B) \u901a\u8fc7\u6fc0\u5149\u5171\u805a\u7126\u663e\u5fae\u955c\u786e\u5b9aCDNP-VT680\u7684\u5206\u5e03\u60c5\u51b5\uff1b<\/p>\n

(C) \u6ce8\u5c04\u540e24\u5c0f\u65f6\uff0c\u89c2\u5bdf\u5230CDNP-VT680\u4ece\u8840\u7ba1\u6e05\u9664\uff1b<\/p>\n

(D)\u6ce8\u5c04\u540e24\u5c0f\u65f6\uff0cCDNP\u9776\u5411\u5206\u5e03\u5230\u80bf\u7624\u90e8\u4f4d\u7684TAMs\u4e2d\u3002<\/p>\n

\u56fe9 CaBP-PEG\u7eb3\u7c73\u9897\u7c92\u76f8\u5173\u8868\u5f81\u53ca\u80bf\u7624\u6cbb\u7597\u6548\u679c<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u751f\u7406\uff08pH 7.4\uff09\u548c\u9178\u6027\uff08pH 6\uff09\u7f13\u51b2\u6db2\u4e2dCaBP-PEG\u7eb3\u7c73\u9897\u7c92\u7684TEM\u56fe\u50cf\uff1b<\/p>\n

(B) DiD\u6807\u8bb0\u7684CaBP-PEG\u7eb3\u7c73\u9897\u7c92\u5728RAW264.7\u7ec6\u80de\u7684\u5b9a\u4f4d\u60c5\u51b5\uff1b<\/p>\n

(C) CaBP-PEG\u7eb3\u7c73\u9897\u7c92\u5728\u4e0d\u540c\u7ec6\u80de\u4e2d\u7684\u534a\u6570\u81f4\u6b7b\u6d53\u5ea6\uff08IC50\uff09\uff1b<\/p>\n

(D) \u4e0d\u540c\u7ec4\u522b\u5c0f\u9f20\u7684\u80bf\u7624\u4f53\u79ef\u66f2\u7ebf\uff1b<\/p>\n

(E) \u4e0d\u540c\u5904\u7406\u540e\u80bf\u7624\u4e2dF4\/80\u9633\u6027\u7ec6\u80de\u7684\u7edf\u8ba1\u5206\u6790\uff1b<\/p>\n

(F) \u4e0d\u540c\u5904\u7406\u540e\u5c0f\u9f20\u8840\u6e05\u4e2dIL-10\u7684\u542b\u91cf\u3002<\/p>\n

\u56fe10 Ferumoxytol\u6291\u5236\u80bf\u7624\u751f\u957f<\/strong><\/p>\n

\"\"(A) \u4e0e\u764c\u7ec6\u80de\u548cFerumoxytol\u5171\u57f9\u517b\u540e\uff0c\u5de8\u566c\u7ec6\u80de\u76f8\u5173\u6781\u5316\u57fa\u56e0\u53d8\u5316\uff1b<\/p>\n

(B, C) \u4e0e\u764c\u7ec6\u80de\u548cFerumoxytol\u5171\u57f9\u517b\u540e\uff0c\u5de8\u566c\u7ec6\u80deTNF-\u03b1\u8868\u8fbe\u589e\u52a0\u800cIL-10\u5206\u6ccc\u51cf\u5c11\uff1b<\/p>\n

(D) \u4e0e\u672a\u5904\u7406\u7684\u5bf9\u7167\u76f8\u6bd4\uff0cFerumoxytol\u6291\u5236\u80bf\u7624\u751f\u957f\uff1b<\/p>\n

(E\uff0cF) \u6709\u65e0Ferumoxytol\u5904\u7406\uff0c\u5728\u690d\u5165\u764c\u7ec6\u80de\u540e7\u5929\uff08E\uff09\u53ca21\u5929\uff08F\uff09\u83b7\u5f97\u7684MMTV-PyMT\u80bf\u7624\u5207\u7247\u7684\u514d\u75ab\u8367\u5149\u67d3\u8272\uff0c\u5176\u4e2dCD11b\uff08\u7ea2\u8272\uff09\u3001CD206\uff08\u7ea2\u8272\uff09\u548cCD80\uff08\u7eff\u8272\uff09\uff1b<\/p>\n

(G, H) \u751f\u7269\u53d1\u5149\u6210\u50cf\u76d1\u6d4b\u809d\u80bf\u7624\u751f\u957f\uff1b<\/p>\n

(I, J) \u901a\u8fc7CD80\u548cCD206\u6807\u8bb0\uff0c\u6d41\u5f0f\u7ec6\u80de\u4eea\u6d4b\u5b9a\u7ec4\u7ec7\u9a7b\u7559\u548c\u6d78\u6da6\u7684\u5de8\u566c\u7ec6\u80de\u5747\u5411M1\u8868\u578b\u6781\u5316\u3002<\/p>\n

\u56fe11 \u8f7d\u6709\u591a\u80bd\u53caRNA\u7684\u91d1\u7eb3\u7c73\u9897\u7c92\u6740\u4f24TAM\u548c\u764c\u7ec6\u80de<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u4e0d\u540c\u5904\u7406\u540e\uff0c\u4eba\u80ba\u817a\u764c\u80bf\u7624\u8377\u7624\u5c0f\u9f20\u7684\u5b9e\u65f6\u6210\u50cf\uff1b<\/p>\n

(B) \u4e0d\u540c\u5904\u7406\u540e\u5c0f\u9f20\u80ba\u7ec4\u7ec7\u751f\u7269\u53d1\u5149\u6210\u50cf\uff1b<\/p>\n

(C) \u4e0d\u540c\u7ec4\u522b\u5c0f\u9f20\u80bf\u7624\u751f\u957f\u66f2\u7ebf\u3002<\/p>\n

\u56fe12 \u5de8\u566c\u7ec6\u80de\u4e0eTiO2-M\u7684\u76f8\u4e92\u4f5c\u7528<\/strong><\/p>\n

\"\"<\/p>\n

(A) SEM\u56fe\u50cf\u663e\u793a\u6d3b\u5316\u7684\u5de8\u566c\u7ec6\u80de\uff1b<\/p>\n

(B) A\u56fe\u4e2d\u65b9\u5f62\u533a\u57df\u7684\u653e\u5927\u56fe\uff1b<\/p>\n

(C) \u9897\u7c92\u7c07\u7684EDX\u5206\u6790\u3002<\/p>\n

\u56fe13 \u5de8\u566c\u7ec6\u80de\u541e\u566c\u91d1\u5c5e\u5bcc\u52d2\u9187<\/strong><\/p>\n

\"\"<\/p>\n

(A) Gd @ C82<\/sub>(OH)22<\/sub>\u7eb3\u7c73\u7c92\u5b50\u7684Gd M-edge NEXAFS\u8c31\u56fe\uff1b<\/p>\n

(B) \u5c0f\u9f20\u539f\u4ee3\u8179\u8154\u5de8\u566c\u7ec6\u80de\u5185Gd@C82<\/sub>(OH)22<\/sub>\u7684\u8f6fX\u5c04\u7ebfSTXM\u53cc\u80fd\u91cf\u5bf9\u6bd4\u56fe\u50cf\uff1b<\/p>\n

(C) \u5c0f\u9f20\u539f\u4ee3\u8179\u8154\u5de8\u566c\u7ec6\u80de\u548cRAW264.7\u7ec6\u80de\u6444\u53d6\u7684Gd@C82<\/sub>(OH)22<\/sub>\u5728\u4e0d\u540c\u65f6\u95f4\u7684\u8f6fX\u5c04\u7ebfSTXM\u53cc\u80fd\u91cf\u5bf9\u6bd4\u56fe\u50cf\uff1b<\/p>\n

(D) \u5c0f\u9f20\u539f\u4ee3\u8179\u8154\u5de8\u566c\u7ec6\u80de\u5728\u4e0d\u540c\u65f6\u95f4\u6444\u53d6\u7684Gd@C82<\/sub>(OH)22<\/sub>\u7684ICP-MS\u5b9a\u91cf\u5206\u6790\u3002<\/p>\n

\u56fe14 Gd@C82<\/sub>(OH)22<\/sub>\u548cC60<\/sub>(OH)22<\/sub>\u7eb3\u7c73\u9897\u7c92\u6fc0\u6d3b\u5de8\u566c\u7ec6\u80de<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u7528\u5728\u6709\u65e0NF-\u03baB\u901a\u8def\u6291\u5236\u529b\u60c5\u51b5\u4e0b\uff0c\u4e0b\u5ba4\u5de8\u566c\u7ec6\u80de\u5bf9\u4e0a\u5ba4\u4e2d\u7684B16\u7ec6\u80de\u7684\u6740\u4f24\u60c5\u51b5\uff0c\u6d3b\u7ec6\u80de\uff08\u7eff\u8272\uff09\uff0c\u6b7b\u7ec6\u80de\uff08\u7ea2\u8272\uff09\uff1b<\/p>\n

(B) CCK-8\u6d4b\u5b9aB16\u7ec6\u80de\u7684\u6d3b\u529b\uff1b<\/p>\n

(C) ELISA\u6d4b\u5b9a\u7ec6\u80de\u57f9\u517b\u4e0a\u6e05\u6db2\u4e2dTNF-\u03b1\u3001IL-1\u03b2\u548cIL-6\u7684\u8868\u8fbe\u3002<\/p>\n

\u56fe15 Macrin\u5b9e\u73b0\u9776\u5411TAM\u7684\u4f53\u5185\u6210\u50cf<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u901a\u8fc7SEM\u6d4b\u91cfMacrin\u9897\u7c92\u76f4\u5f84\u7684\u5206\u5e03\uff1b<\/p>\n

(B) C57BL\/6\u5c0f\u9f20\u6ce8\u5c04Macrin\u9897\u7c9224\u5c0f\u65f6\u540e\u53cc\u4fa7\u540e\u817fMC38\u80bf\u7624PET\/CT\u6210\u50cf\u91cd\u5efa\uff1b<\/p>\n

(C) MC38\u80bf\u7624\u4f53\u5185\u6fc0\u5149\u5171\u805a\u7126\u6210\u50cf\uff1b<\/p>\n

(D) \u57fa\u4e8e(C)\u56fe\uff0c\u901a\u8fc7\u8367\u5149\u6570\u636e\u5206\u6790Macrin\u4f53\u5185\u6444\u53d6\u60c5\u51b5\uff1b<\/p>\n

(E) MC38\u7ec6\u80de\u53ca\u9aa8\u9ad3\u6765\u6e90\u7684\u5de8\u566c\u7ec6\u80de\u5bf9VT680-Macrin\u7684\u4f53\u5916\u6444\u53d6\u60c5\u51b5\u3002<\/p>\n

\u56fe16 \u76d1\u6d4bTAM\u9884\u6d4b\u4e0d\u540c\u7eb3\u7c73\u836f\u7269\u7684\u6cbb\u7597\u6548\u679c<\/strong><\/p>\n

\"\"<\/p>\n

(A) \u6574\u4e2a\u80ba\u53f6\u4e2d\u7684Macrin\uff08\u767d\u8272\uff09\u3001PLGA-PEG\u7eb3\u7c73\u9897\u7c92\uff08\u7ea2\u8272\uff09\u548cGFP+<\/sup> KP\u80bf\u7624\uff08\u7eff\u8272\uff09\u5206\u5e03\u60c5\u51b5\uff1b<\/p>\n

(B) \u80ba\u90e8\u80bf\u7624\u5bf9Macron\u7684\u6444\u53d6\uff1b<\/p>\n

(C) \u80ba\u90e8\u80bf\u7624\u5bf9PLGA-PEG \u7eb3\u7c73\u9897\u7c92\u7684\u6444\u53d6\uff1b<\/p>\n

(D) \u7eb3\u7c73\u9897\u7c92\u5728\u975e\u80bf\u7624\u7ec4\u7ec7\u4e2d\u7684\u5206\u5e03\uff1b<\/p>\n

(E) \u4e0d\u540c\u5904\u7406\u540e\uff0c\u80bf\u7624\u5bf9\u7eb3\u7c73\u9897\u7c92\u6444\u53d6\u7684\u76f8\u5173\u6027\uff1b<\/p>\n

(F) \u4e0d\u540c\u5927\u5c0fKP\u80bf\u7624\u5bf9PLGA-PEG \u7eb3\u7c73\u9897\u7c92\u7684\u6444\u53d6\u3002<\/p>\n

\u3010\u5c0f\u7ed3\u3011<\/strong><\/p>\n

\u5728\u8be5\u7efc\u8ff0\u4e2d\uff0c\u4f5c\u8005\u603b\u7ed3\u4e86TAMs\u76f8\u5173\u751f\u7269\u5b66\u673a\u5236\u548cTAMs\u7684\u9776\u5411\u7b56\u7565\uff08\u7b2c2\u8282\u548c\u7b2c3\u8282\uff09\uff0c\u91cd\u70b9\u5173\u6ce8\u4e86\u9776\u5411TAMs\u751f\u7269\u6750\u6599\u7684\u8bbe\u8ba1\uff08\u7b2c4\u8282\uff09\uff0c\u6700\u540e\u6982\u8ff0\u4e86\u901a\u8fc7\u7eb3\u7c73\u9897\u7c92\u6210\u50cfTAMs\u7684\u7814\u7a76\u8fdb\u5c55\uff08\u7b2c5\u8282\uff09\u3002\u4f5c\u8005\u7740\u773c\u4e8e\u764c\u75c7\u514d\u75ab\u7eb3\u7c73\u533b\u5b66\u9886\u57df\u7684\u672a\u6765\u53d1\u5c55\uff0c\u5f3a\u8c03\u4e86\u764c\u75c7\u514d\u75ab\u7eb3\u7c73\u533b\u5b66\u5df2\u7ecf\u6210\u4e3a\u6c9f\u901a\u7eb3\u7c73\u6280\u672f\u3001\u80bf\u7624\u5b66\u548c\u514d\u75ab\u5b66\u7b49\u4e0d\u540c\u9886\u57df\u7684\u6865\u6881\u548c\u7ebd\u5e26\u3002\u6b64\u5916\uff0c\u4f5c\u8005\u8fd8\u6307\u51fa\uff1a1. \u5229\u7528\u9ad8\u901a\u91cf\u65b9\u6cd5\u8fdb\u884c\u5168\u9762\u7684\u8868\u578b\u5206\u6790\u6709\u671b\u4e3a\u5f00\u53d1\u4e13\u95e8\u9488\u5bf9TAMs\u7684\u5148\u8fdb\u6750\u6599\u63d0\u4f9b\u6709\u529b\u6570\u636e\uff1b2. \u8ddf\u8e2a\u7eb3\u7c73\u9897\u7c92\u5728\u7ec6\u80de\u5185\u7684\u8fd0\u8f93\u884c\u4e3a\u5bf9\u4e8e\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u548c\u6210\u50cf\u5177\u6709\u91cd\u8981\u610f\u4e49\uff1b3.\u9776\u5411TAMs\u7684\u7eb3\u7c73\u836f\u7269\u5728\u4e34\u5e8a\u8f6c\u5316\u524d\uff0c\u4ecd\u9700\u8981\u8fdb\u4e00\u6b65\u7684\u673a\u5236\u7814\u7a76\u4ece\u800c\u63d0\u4f9b\u66f4\u4e2a\u6027\u5316\u7684\u6cbb\u7597\u65b9\u6848\u548c\u66f4\u6709\u6548\u7684\u9776\u5411\u6cbb\u7597\u3002<\/p>\n

\u6587\u732e\u94fe\u63a5\uff1aTailoring Nanomaterials for Targeting Tumor-Associated Macrophages<\/a>\u00a0(Adv. Mater. 2019, DOI: 10.1002\/adma.201808303)<\/strong><\/p>\n

\u3010\u56e2\u961f\u4ecb\u7ecd\u3011<\/strong><\/p>\n

\u8bfe\u9898\u7ec4\u5efa\u4e8e2006\u5e746\u6708\uff0c\u96b6\u5c5e\u4e8e\u4e2d\u79d1\u9662\u7eb3\u7c73\u751f\u7269\u6548\u5e94\u4e0e\u5b89\u5168\u6027\u91cd\u70b9\u5b9e\u9a8c\u5ba4\uff0c\u7531\u7814\u7a76\u5458\u3001\u526f\u7814\u7a76\u5458\uff0c\u9ad8\u7ea7\u5de5\u7a0b\u5e08\u3001\u52a9\u7406\u7814\u7a76\u5458\u53ca\u535a\u58eb\u540e\u3001\u535a\u58eb\u751f\u3001\u7855\u58eb\u751f\u3001\u8054\u5408\u57f9\u517b\u5b66\u751f\u6784\u6210\u3002\u672c\u8bfe\u9898\u7ec4\u5148\u540e\u627f\u62c5\u79d1\u6280\u90e8\u56fd\u5bb6\u91cd\u70b9\u7814\u53d1\u8ba1\u5212\u7eb3\u7c73\u4e13\u9879\u3001973\u9879\u76ee\u8bfe\u9898\u3001\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u57fa\u91d1\u3001\u6b27\u76df\u5730\u5e73\u7ebf2020\u9879\u76ee\u3001\u6b27\u76df\u7b2c\u516d\u3001\u7b2c\u4e03\u6846\u67b6\u8ba1\u5212(EU-FP6&FP7)\u3001\u56fd\u9645\u539f\u5b50\u80fd\u673a\u6784\u534f\u8c03\u7814\u7a76\u8ba1\u5212(IAEA)\u7b49\u591a\u9879\u56fd\u5185\u4e0e\u56fd\u9645\u5408\u4f5c\u9879\u76ee\u3002\u5728\u56fd\u9645\u91cd\u8981\u671f\u520a\u53d1\u8868\u8bba\u6587200\u4f59\u7bc7\uff0c\u4e2d\u56fd\u6388\u6743\u4e13\u522918\u9879\uff0c\u56fd\u9645\u6388\u6743\u4e13\u52291\u9879\u3002\u8bfe\u9898\u7ec4\u957f\u9648\u6625\u82f1\u7814\u7a76\u5458\u4e8e2018\u5e74\u83b7\u201c\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u4e8c\u7b49\u5956\u201d\uff0c2017\u5e74\u88ab\u8bc4\u4e3a\u4e2d\u56fd\u79d1\u5b66\u9662\u7b2c\u4e94\u5c4a\u201c\u5341\u5927\u6770\u51fa\u5987\u5973\u201d \uff0c2014\u5e74\u83b7\u4e2d\u56fd\u9752\u5e74\u5973\u79d1\u5b66\u5bb6\u5956\uff0c\u591a\u6b21\u5165\u9009\u5168\u7403\u9ad8\u5f15\u7528\u79d1\u5b66\u5bb6\uff0c2011\u5e74\u83b7\u201c\u4e2d\u56fd\u6807\u51c6\u5316\u6770\u51fa\u4eba\u7269\u2014\u521b\u65b0\u4eba\u7269\u5956\u201d\uff0c2012\u5e74\u83b7\u201c\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u4e8c\u7b49\u5956(2)\u201d\u30022018\u5e74\u5f53\u9009\u4e9a\u6d32\u6bd2\u7406\u5b66\u4f1a\u79d8\u4e66\u957f\u3002\u8bfe\u9898\u7ec4\u5185\u4f18\u97521\u4eba\uff0c\u5b66\u751f\u8363\u83b7\u56fd\u5bb6\u5956\u5b66\u91d15\u4eba\uff0c\u6731\u674e\u6708\u534e\u59561\u4eba\uff0c\u4f18\u79c0\u6bd5\u4e1a\u751f1\u4eba\uff0c\u4f18\u79c0\u5b66\u751f\u6807\u51753\u4eba\uff0c2017\u5e74\u8bfa\u8d1d\u5c14\u5956\u83b7\u5f97\u8005\u5927\u4f1a\u4e2d\u56fd\u53c2\u4f1a\u4ee3\u88681\u4eba\u3002<\/p>\n

\u3010\u56e2\u961f\u5728\u8be5\u9886\u57df\u7684\u5de5\u4f5c\u6c47\u603b\u3011<\/strong><\/p>\n

\u56e2\u961f\u9488\u5bf9\u7eb3\u7c73\u6750\u6599\u7279\u522b\u662f\u78b3\u7eb3\u7c73\u6750\u6599\u7684\u514d\u75ab\u5b66\u6548\u5e94\u8fdb\u884c\u4e86\u4e00\u7cfb\u5217\u7684\u7814\u7a76\u3002\u6211\u4eec\u53d1\u73b0\u964d\u4f4e\u8840\u6db2\u86cb\u767d\u5206\u5b50\u5728\u7eb3\u7c73\u6750\u6599\u8868\u9762\u7684\u5438\u9644\u548c\u8c03\u7406\u4f5c\u7528\uff0c\u662f\u8c03\u63a7\u5176\u751f\u7269\u533b\u5b66\u7279\u6027\u4e0e\u529f\u80fd\u7684\u5173\u952e\u4e4b\u4e00\u3002\u5bcc\u52d2\u9187\u7684\u91d1\u5c5e\u884d\u751f\u7269\uff0cGd@C82<\/sub>(OH)22<\/sub>\u5177\u6709\u8f83\u597d\u7684\u514d\u75ab\u523a\u6fc0\u4f5c\u7528\u53ca\u8f83\u4f4e\u7684\u6bd2\u526f\u4f5c\u7528\uff0c\u901a\u8fc7\u523a\u6fc0T\u7ec6\u80de\u548c\u5de8\u566c\u7ec6\u80de\u5206\u6ccc\u4fc3\u708e\u56e0\u5b50TNF-\u0430\u548cIFN-\u03b3\u6765\u6291\u5236\u80bf\u7624\u751f\u957f1<\/sup>\u3002\u540c\u65f6\uff0c\u6211\u4eec\u5229\u7528\u540c\u6b65\u8f90\u5c04\u6280\u672f\u68c0\u6d4b\u4e86\u91d1\u5c5e\u5bcc\u52d2\u9187\u5728\u5de8\u566c\u7ec6\u80de\u5185\u7684\u5206\u5e03\u60c5\u51b5\uff0c\u6df1\u5165\u7814\u7a76\u4e86\u91d1\u5c5e\u5bcc\u52d2\u9187\u6fc0\u6d3b\u5de8\u566c\u7ec6\u80de\u7684\u5177\u4f53\u673a\u52362<\/sup>\u3002\u6211\u4eec\u4e5f\u5229\u7528\u91d1\u5c5e\u5bcc\u52d2\u9187\u5904\u7406\u540e\u6781\u5316\u4e3aM1\u578b\u7684\u5de8\u566c\u7ec6\u80de\u5bf9\u8377\u7624\u5c0f\u9f20\u8fdb\u884c\u7ec6\u80de\u56de\u8f93\u6cbb\u7597\uff0c\u53d1\u73b0M1\u578b\u5de8\u566c\u7ec6\u80de\u901a\u8fc7\u5206\u6ccc\u4fc3\u708e\u56e0\u5b50\u8fbe\u5230\u4e86\u660e\u663e\u7684\u6291\u7624\u6548\u679c\u3002<\/p>\n

1. Rong Cai, Chunying Chen*. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine. Advanced Materials, 2018, 1805740.<\/p>\n

2. Jiaming Liu, Chunying Chen*, Yuliang Zhao*. Progress and Prospects of Graphdiyne\u2010Based Materials in Biomedical Applications. Advanced Materials, 2019, 1804386.<\/p>\n

3. Jiangfeng Du, Zhanjun Gu*, Liang Yan, Yuan Yong, Xuan Yi, Xiao Zhang, Jing Liu, Renfei Wu, Cuicui Ge, Chunying Chen*, Yuliang Zhao*. Poly (Vinylpyrollidone) and Selenocysteine Modified Bi2Se3 Nanoparticles Enhance Radiotherapy Efficacy in Tumor and Promote Radioprotection in Normal Tissues. Advanced Materials, 2017, 29: 1701268.<\/p>\n

4. Cuicui Ge, Jiangfeng Du, Lina Zhao, Liming Wang, Ying Liu, Denghua Li, Yanlian Yang, Ruhong Zhou*, Yuliang Zhao*, Zhifang Chai, Chunying Chen*. Binding of Blood Proteins to Carbon Nanotubes Reduces Cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(41): 16968-16973.<\/p>\n

5. Zhiyun Chen, Ying Liu, Baoyun Sun, Han Li, Jinquan Dong, Lijuan Zhang, Liming Wang, Peng Wang, Yuliang Zhao, Chunying Chen*. Polyhydroxylated Metallofullerenols Stimulate IL-1 Secretion of Macrophage through TLRs\/MyD88\/NF-\u03baB Pathway and NLRP3 Inflammasome Activation. Small, 2014, 10(12): 2362-2372.<\/p>\n

6. Jinglong Tang, Zhiyun Chen, Baoyun Sun, Jinquan Dong,\u00a0 Jing Liu, Huige Zhou, Liming Wang, Ru Bai, Qing Miao, Yuliang Zhao, Chunying Chen, Ying Liu*. Polyhydroxylated Fullerenols Regulate Macrophage for Cancer Adoptive Immunotherapy and Greatly Inhibit the Tumor Metastasis. Nanomedicine: Nanotechnology, Biology and Medicine, 2016, 12(4): 945-954.<\/p>\n

\u3010\u76f8\u5173\u4f18\u8d28\u6587\u732e\u63a8\u8350\u3011<\/strong><\/p>\n

1. Hua Wang and David J. Mooney. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nature materials, 2018, 17, 761-772.<\/p>\n

2. Luca Cassetta and Jeffrey W. Pollard. Targeting macrophages: therapeutic approaches in cancer. Nature reviews drug discovery, 2018, 17, 887-904.\u00a0<\/p>\n

3. Saeid Zanganeh, GregorHutter, Ryan Spitler, Jukka Sakari Pajarinen6, Hossein Nejadni, Lisa Marie Coussens and Heike Elisabeth Daldrup-Link, Olga Lenkov, Stuart Goodman, Morteza Mahmoudi, Michael Moseley. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature nanotechnology, 2016, 11, 986-994.\u00a0<\/p>\n

4. Christopher B. Rodell, Sean P. Arlauckas, Michael F. Cuccarese, Christopher S. Garris, Ran Li, Maaz S. Ahmed, Maaz S. Ahmed, Rainer H. Kohler, Mikael J. Pittet and Ralph Weissleder. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nature Biomedical engineering, 2018, 2, 578-588.<\/p>\n

 <\/p>\n

\u672c\u6587\u7531\u6750\u6599\u4eba\u751f\u7269\u5b66\u672f\u7ec4biotech\u4f9b\u7a3f\uff0c\u6750\u6599\u725b\u5ba1\u6838\u6574\u7406\u3002<\/p>\n

\u6b22\u8fce\u5927\u5bb6\u5230\u6750\u6599\u4eba\u5ba3\u4f20\u79d1\u6280\u6210\u679c\u5e76\u5bf9\u6587\u732e\u8fdb\u884c\u6df1\u5165\u89e3\u8bfb\uff0c\u6295\u7a3f\u90ae\u7bb1tougao@cailiaoren.com\u3002<\/p>\n

\u6295\u7a3f\u53ca\u5185\u5bb9\u5408\u4f5c\u53ef\u52a0\u7f16\u8f91\u5fae\u4fe1\uff1acailiaorenkefu\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u3010\u5f15\u8a00\u3011 \u80bf\u7624\u514d\u75ab\u6cbb\u7597\u80fd\u591f\u8c03\u8282\u81ea\u8eab\u514d\u75ab\u7cfb\u7edf\u5e76\u6062\u590d\u673a\u4f53\u6b63\u5e38\u7684\u6297\u80bf\u7624\u514d\u75ab\u53cd\u5e94\u3002\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u57fa\u7840\u7814\u7a76\u7684\u5173\u952e\u8fdb\u6b65\u5df2\u7ecf\u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u53d6\u5f97\u663e\u8457\u7684\u6cbb\u7597\u6548\u679c\uff0c\u6781\u5927\u6539\u5584\u4e86\u6076\u6027\u80bf\u7624\u60a3…<\/p>\n","protected":false},"author":7746,"featured_media":171182,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[533],"tags":[3962,2527],"class_list":["post-171180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zongshu","tag-3962","tag-2527"],"_links":{"self":[{"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/posts\/171180"}],"collection":[{"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/users\/7746"}],"replies":[{"embeddable":true,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=171180"}],"version-history":[{"count":3,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/posts\/171180\/revisions"}],"predecessor-version":[{"id":171553,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/posts\/171180\/revisions\/171553"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=\/wp\/v2\/media\/171182"}],"wp:attachment":[{"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=171180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=171180"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.cailiaoniu.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=171180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}